Meridian Bioscience, Inc. reported earnings results for the full year ended September 30, 2022. For the full year, the company reported sales was USD 333.02 million compared to USD 317.9 million a year ago. Net income was USD 42.46 million compared to USD 71.41 million a year ago.

Basic earnings per share from continuing operations was USD 0.97 compared to USD 1.65 a year ago. Diluted earnings per share from continuing operations was USD 0.96 compared to USD 1.62 a year ago.